GLP-1 drugs and your face: what 'face card' TikTok gets wrong

What did @glo.by.d actually say?

Not much, medically speaking. The transcript from this 1.2 million-view video is: "Hey wanna hang with a baby, she wanna hang with a baby." That's it. There are no claims about GLP-1 medications, no dosing advice, no before-and-after promises, and no health assertions of any kind. The caption reads "Face card never declining babe!" which is slang for staying attractive, but even that isn't a specific medical claim. This is essentially a vibe video that got tagged under the GLP-1 category, likely by algorithm or hashtag association.

So what is there to fact-check? Technically, very little. But given this landed in front of 1.2 million people under a GLP-1 content umbrella, it's worth using the moment to talk about what the "face card" conversation around these medications actually involves, because that conversation is happening constantly on this platform, even if this particular creator didn't make any specific claims here.

Does the science back this up?

There's no claim to evaluate directly, but the implied association between GLP-1 medications and looking good is worth examining. The science is real, but complicated. Weight loss from semaglutide or tirzepatide does change how people look, and that's documented. What's less flattering in the research is what's sometimes called "Ozempic face."

A 2023 commentary in JAMA Dermatology by Hwang and colleagues noted that rapid weight loss associated with GLP-1 receptor agonists can cause facial volume loss, making users appear gaunt or aged despite lower body weight. This isn't universal, and it's more common with faster or more dramatic weight loss. On the other hand, researchers including those behind the SELECT trial (Lincoff et al., 2023, NEJM) found semaglutide significantly reduced cardiovascular events, which has its own long-term quality-of-life implications. Looking good and being healthier are not always the same thing, and the "face card" framing flattens a more textured clinical picture.

What did they get wrong (or right)?

Since @glo.by.d made no verifiable health claims, there's nothing to correct on the facts. That's actually somewhat refreshing in a space overloaded with people confidently explaining dosing protocols they read on Reddit. The creator didn't tell anyone to inject anything, didn't claim a drug treats a specific condition, and didn't make before-and-after promises. Credit where it's due.

The concern is more ambient. The association of GLP-1 medications with "face card never declining" feeds a purely cosmetic framing of drugs that were developed for metabolic disease management. When aesthetic outcomes become the primary cultural story around semaglutide and tirzepatide, it distorts public understanding of who these medications are actually for, what the risks look like, and why supply shortages affect people with type 2 diabetes who depend on them. That's not this creator's fault specifically, but it's the context their content lives inside.

What should you actually know?

GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) are FDA-approved medications with meaningful clinical evidence behind them. They are not primarily beauty drugs, even if weight loss sometimes has cosmetic effects. The SELECT trial showed a 20% reduction in major cardiovascular events in adults with obesity and established cardiovascular disease. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide producing up to 22.5% mean body weight reduction, but also documented side effects including nausea, vomiting, and gastrointestinal issues in a significant portion of participants.

Facial changes from rapid weight loss are real and documented. If the cosmetic outcome of these medications is a selling point for you, that's a conversation worth having with a licensed provider who can contextualize it against the full risk-benefit profile. No TikTok video, including this one, replaces that conversation.